Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The post said that insider buying was up..that's the figures posted.
Off another board..inside CYDY buying up Pestell (Richard G) 17.6M $4,940,283 +35% 3.1%
Welch (David F) 12.5M $37,046,232 +25% 2.2%
Patel (Samir ... 7.2M $21,367,867 +14% 1.3%
Naydenov 6.1M $18,167,956 +12% 1.1%
Caracciolo ... 2.6M $1,497,623 +5% 0.5%
Kelly (Scott A) 2.3M $6,818,123 +5% 0.4%
HUGE! UCLA Doctor Says Leronlimab Cures 2nd Phase of Coronavirus https://t.co/AFvZRg36BL via @realmattcouch
— Janie Johnson - America is Exceptional (@jjauthor) August 26, 2020
Can you elaborate? I'm kid of seeing where your going with this but just want to make sure
Nader could have waited until morning for this PR. Something is up, he's leaving tomorrow morning open for a blast of sunshine!!!
LOL..link? Where do you come up with this stuff? So you're saying they failed? Proof?
this out to put your EUA non factual banter to rest- FDA responded.
“Dr. Marks,
I'm curious about the hold up regarding Leronlimab. It has met the thresholds for an Emergency Use Authorization for use as a treatment for Covid-19. It has been proven, using a multi center double blind, randomized, placebo controlled Phase II study, to be efficacious against SARS-CoV-2 in the the mild to moderate patient population; in a study approved by the FDA. And, Leronlimab has a proven safety profile as demonstrated in studies of over 1,000 patients, for HIV and SARS-CoV-2.
In light of the retrospective and anecdotal evidence used to give Convalescent Plasma an Emergency Use Authorization for use as a treatment in a very narrow subset of early Covid-19 patients, I am left scratching my head as how a multi center double blind, randomized, placebo controlled study of any size could be negated by retrospective and non-blind, non-randomized, and non-use of placebos in uncontrolled studies of even the largest sample sizes (ie. 70,000 patient Mayo study).
I can attest to the fact that myself, and many Physicians and Healthcare Providers are feeling frustrated by what appears to be favoritism played towards large Pharmaceutical Companies who have staff working at the FDA as Consultants. While patients continue to die of inflammation related disorders, due to the out-of-control immune response to the SARS-CoV-2 attack, it seems almost neglectful to offer Remdesivir and supportive measures to such patients. An antiviral vaccine is supposed to be preventative, not used as a therapy for an already induced immune response. And, the use of steroids is contraindicated in patients not requiring oxygen. In addition, comparatively speaking, Leronlimab versus steroids, does not suppress the immune system, but enhances it, reducing viral load to zero, as it reduces inflammation.
So, for mild to moderate patients, Leronlimab is proven to be the most effective against SARS-CoV-2, versus Remdesivir, Steroids and Convalescent Plasma. This patient population is important to treat early for many reasons besides just preventing potential worsening of progression towards serious illness. Our medical community has been overwhelmed by the large influx of SARS-CoV-2 patients, to the detriment of other serving other types of maladies, which include trauma as more people re-enter the workforce. Healthcare Providers need help in getting patients out of the hospitals as quickly as possible. Lest we not forget the cost savings of such measures.
I implore you to ensure that Leronlimab moves quickly through the Emergency Use Authorization process. It needs to be another tool Practitioners can rely on to bring the Pandemic under control!!“
The poster got a generic response.
“Thank you for contacting Dr. Peter Marks. Please accept this response from the Division of Drug Information, in the FDA’s Center for Drug Evaluation and Research.
FDA has created a special emergency program for possible therapies, the Coronavirus Treatment Acceleration Program (CTAP). It uses every available method to move new treatments to patients as quickly as possible, while at the same time finding out whether they are helpful or harmful. We continue to support clinical trials that are testing new treatments for COVID so that we gain valuable knowledge about their safety and effectiveness.
Please note that due to confidentiality laws, the FDA cannot divulge information related to applications that may or may not have been submitted to the Agency. All information on an unapproved drug product is confidential and belongs to the sponsor. We understand this can be frustrating when you are just trying to treat the patients.
We encourage you to report, and encourage other physicians to report, your experiences with COVID therapies through CURE ID, an internet-based repository that lets the clinical community report novel uses of existing drugs for difficult-to-treat infectious diseases through a website, a smartphone or other mobile device. More information is available here.
For more information on Emergency Use Authorizations (EUAs), visit:
Emergency Use Authorization
Best Regards,
Holli
Pharmacist
Division of Drug Information
Center for Drug Evaluation and Research
Tel: 855-543-DRUG (855-543-3784)
druginfo@fda.hhs.gov
(16) (0)
A little bit of fact--NP is quiet now but not for long. quite a few NDA's involved. It's all good.
OK!!! Upticks, downticks, candlesticks it's all worthless with CYDY. One huge PR ( which is coming soon) and your charting turns into antics.
Amazing facts! Thank You!!!
Sell your shares? 5.95? Now? Hold off, OWS news is gonna get CYDY to at least 7.00 tomorrow.
Top economist and hedge fund manager knows about Leronlimab..interesting isn't it?
Here's the full paragraph:
Operation Warp Speed (OWS) aims to deliver 300 million doses of a safe, effective vaccine for COVID-19 by January 2021, as part of a broader strategy to accelerate the development, manufacturing, and distribution of COVID-19 vaccines, therapeutics, and diagnostics (collectively known as countermeasures).
Great tweet on Leronlimab
@NYGovCuomo Ask the MD’s at Montefiore Medical Ctr. how well leronlimab worked in “emergency treatment” for Covid. Then ask @US_FDA why it’s not been approved as the treatment. @KGreenbergMD @nypost @nytimes @SPECNewsAlbany @LongIslandPress
— Mitchell (Ukrainian) Roffer, Ph.D. (@MitchRoffer) August 16, 2020
Thats a repost. Saw that article 3 months ago
Does anyone on this board feel that Nader was "told" to stop the Mexico trial from the Trump Administration? Use your head people.
What paragraph is before that? Can you post that?
Whats the date of that?
Whats the date on your link?
On June 10, 2020 and July 27, 2020, the Company entered into Amendment #1 and Amendment #2, respectively, to the Samsung Agreement to increase the purchase order quantity of total drug substance batches to be produced during calendar year 2020 by seven batches for a total of 13 batches. Two batches have already been manufactured as of May 31, 2020. The incremental seven batches to be manufactured during calendar year 2020 will be reduced against the number of forecasted batches the Company planned to have manufactured during calendar year 2021. As part of this arrangement Samsung has allowed for the deferral of payments of certain costs to calendar years 2020, 2021 and 2022. These amendments increase the approximate contract commitment to approximately $103 million from approximately $60 million.”
Here's a fact
Some interesting info. Looks like Leronlimab may be given a nod sooner than we think:
EUA on the Agency website (www.fda.gov).
Timelines for Review: The timelines for FDA review and action on a request for consideration for an EUA
will depend on the product profile; the existence, if any, of pending applications for the product; the nature of
the emergency; and other relevant factors. Although the length of time required for FDA action will vary, the
Agency recognizes that it is likely that, in an emergency situation that is occurring or believed imminent, a
request for consideration for an EUA will be acted upon within a matter of hours or days.
Stop with the NP and Paterson " split" rumors. You're all going to be shocked and eat your words as to why Paterson is not in the picture right now. It's for Cytodyns and Patersons benefit. Let's say it's a ethical decision....for now.
This is getting comical now. Really???? CYDY$$$$$$$
hahaha...you're going to regret selling! Have you been paying attention to the news? My guess is you havent
Trump once again mentions a 'shot". Got to be Leronlimab. Could Nader know already? Tight lipped at the Trump Administrations wishes? Waiting for vials to arrive???
Post the rest of it!!!
Nice!!!
Just spoke to a doctor friend of mine. He made a great point about Leronlimab. He watched a few videos with Dr. P and Dr L and he seems to think approval is guaranteed but even more interesting is that he stated that Leronlimab can be used as a general anti viral for any virus being it brings the levels to zero in 14 days. He feels very strongly that it can be classified as an anti viral as well as everything else. He's going to reach out to Nader to try and start a dialogue and to get more info on a clinical trial site set up in the hospital he works at as well as his practice.
Off of other boards: There's been talk of Cytodyn retaining top notch investigators to tie bashing to big pharma. Oh oh. One other post also said they are looking at AF and his squad. Smart move if true
from another board and so true. $$$$$$$
1. We Observe consistent positive results from the 65 EIND’s.
2. We receive testimonials from Samantha Mottet who wAs removed from ecmo and recovered .
3. Testimonial from
Chris Riley who participated in the m/m trial and recovered.
4. Testimonial from Dr. Recknor who took part in a EIND and recovered.
5. Dr Patterson thesis on MOA written which confirms why Leronlimab works.
6 . The 23 year girl who took part in the m/m trial and recovered.
7. The reporting on the positive SAE results.
8. Todays release of implied
Efficacy and safety profile.
Link to that mis information???/
Looked at the filings, had my broker look at the filings and guess what? All your accusations of " dumping" are dead wrong. So you're saying the FDA is in on the big "scam"? Come on man, wake up and open your eyes, Cytodyn is going to be HUGE!
I highly doubt that!! Cytodyn is set up to break records as far as leronlimab and stock price goes. They are well on their way to make it a household and hospital common named drug
Is there a chance this can be halted by the DSMC? Maybe Nader is setting up another PR???
You may see a halt in trading then he announces some great news. Then what? Oh, I can see then what no problem.
Dumped or coded "F" for tax liability for shares acquired? DEBUNKED.
CYDY$$$$$$$
That's an old one..try again. Nice photo shop technique
Dumping? Look at the codes - A = bought, F is coded to pay the taxes up front. Stop it already
I'm with you on that. A " shot" . We're the only one!!!!